Ofatumumab and Relapsed CLL 

Interim results from PROLONG, an open-label, two-arm phase III randomised study that compared ofatumumab versus observation in patients in remission following induction treatment for relapsed chronic lymphocytic leukaemia, were presented at the 2014 American Society of Hematology annual meeting.


Patients (n = 474) from Europe and the USA were randomised prior to the interim analysis. The median progression-free survival – the primary end point – was 28.6 months for ofatumumab and 15.2 months for observation (HR = 0.48; p<0.0001). Those receiving ofatumumab had a significantly longer time to the start of the next treatment compared with those in the observation arm (median 38.0 vs. 27.4 months, HR = 0.63; p = 0.0076).

Click here for the full article.



Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.